Search research articles
Contact Us
Filters
Showing results (141-150 of 204) with videos related to
Page
of 21
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 30, 2018
Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis
Devyani Deshpande, Shashikant Srivastava, Eric Nuermberger, et al.
The Lancet. Respiratory Medicine
|
September 6, 2019
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis
Keertan Dheda, Tawanda Gumbo, Gary Maartens, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 30, 2018
Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis
Jotam G Pasipanodya, Wynand Smythe, Corinne S Merle, et al.
Journal of Global Antimicrobial Resistance
|
December 21, 2021
An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease
Shashikant Srivastava, Jotam G Pasipanodya, Scott K Heysell, et al.
Antimicrobial Agents and Chemotherapy
|
June 7, 2017
Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis
Shashikant Srivastava, Gesham Magombedze, Thearith Koeuth, et al.
Biorxiv : the Preprint Server for Biology
|
August 13, 2025
Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens for <i>Mycobacterium abscessus</i> Lung Disease
Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 16, 2016
Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests
Soumya Swaminathan, Jotam G Pasipanodya, Geetha Ramachandran, et al.
Antimicrobial Agents and Chemotherapy
|
April 9, 2026
Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for <i>Mycobacterium abscessus</i> lung disease
Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 30, 2018
Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment
Mathieu S Bolhuis, Onno W Akkerman, Marieke G G Sturkenboom, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 17, 2017
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis
Neesha Rockwood, Jotam G Pasipanodya, Paolo Denti, et al.
Page
of 21
Search research articles
Search
Showing results (141-150 of 204) with videos related to
Sort By:
Page
of 21
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 30, 2018
Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis
Devyani Deshpande, Shashikant Srivastava, Eric Nuermberger, et al.
The Lancet. Respiratory Medicine
|
September 6, 2019
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis
Keertan Dheda, Tawanda Gumbo, Gary Maartens, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 30, 2018
Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis
Jotam G Pasipanodya, Wynand Smythe, Corinne S Merle, et al.
Journal of Global Antimicrobial Resistance
|
December 21, 2021
An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease
Shashikant Srivastava, Jotam G Pasipanodya, Scott K Heysell, et al.
Antimicrobial Agents and Chemotherapy
|
June 7, 2017
Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis
Shashikant Srivastava, Gesham Magombedze, Thearith Koeuth, et al.
Biorxiv : the Preprint Server for Biology
|
August 13, 2025
Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens for <i>Mycobacterium abscessus</i> Lung Disease
Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 16, 2016
Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests
Soumya Swaminathan, Jotam G Pasipanodya, Geetha Ramachandran, et al.
Antimicrobial Agents and Chemotherapy
|
April 9, 2026
Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for <i>Mycobacterium abscessus</i> lung disease
Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 30, 2018
Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment
Mathieu S Bolhuis, Onno W Akkerman, Marieke G G Sturkenboom, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 17, 2017
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis
Neesha Rockwood, Jotam G Pasipanodya, Paolo Denti, et al.
Page
of 21